A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA).
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Dilmapimod (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 13 Jan 2012 Actual patient number is 78 according to ClinicalTrials.gov.
- 13 Jan 2012 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.